Plaque eating nanoparticle prevents heart attacks

Plaque eating nanoparticle prevents heart attacks

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Studies suggest a new Trojan horse nanoparticle can eat-up artery-narrowing plaque – a common cause of heart attacks.

Scientists at Michigan State University have invented a nanoparticle which devours the plaque which can lead to heart attacks. The particle, which has been dubbed a Trojan Horse has the potential to reduce the risks of most types of heart attacks [1].

Longevity.Technology: Once over the age of 40, people have a 50% chance of developing atherosclerosis; a drug that could reduce its consequences has the potential to counter one of the biggest risk factors for heart attacks.

Atherosclerosis, is a leading underlying cause of heart disease and occurs when plaque builds up and blocks the arteries. When it breaks away, it can cause clots which lead to a heart attack.

This new Michigan State nanoparticle, according to results published in Nature Nanotechnology [2], targets atherosclerotic plaque thanks to a high selectivity for certain types of immune cells, monocytes and macrophages. Once inside, it delivers a drug agent which stimulates the cells to eat cellular debris. In other words, it removes the diseased cells buried in the core of the plaque, reinvigorates the macrophages and reduces plaque size.

“We found we could stimulate the macrophages to selectively eat dead and dying cells – these inflammatory cells are precursor cells to atherosclerosis – that are part of the cause of heart attacks,” [2] said Bryan Smith associate professor of biomedical engineering at MSU. “We could deliver a small molecule inside the macrophages to tell them to begin eating again.”

Smith hopes future trials will prove it can reduce most types of heart attacks. The highly selective nature of the drug should mean there are relatively few side effects. While previous studies have focused on the surface of the cell, this new approach penetrates the cell and attacks from the inside out.

Smith has high hopes for the drug and believes it could have applications far beyond atherosclerosis. He has filed a provisional patent and plans to begin marketing it later this year.
[1] https://bit.ly/2RChJQ4
[2] https://www.nature.com/articles/s41565-019-0619-3

Image credit: Image by Narupon Promvichai / Pixabay

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Alzheimer’s drug market faces a $14.7bn future

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE